Although we showed C/EBPα silencing is not oncogenic in the lung, a potential risk of C/EBPα silencing in the lung by treatment with p38 MAP kinase inhibitors should be given a caution and these patients require screening for lung cancer. This evidence concerns the gene CEBPA and lung cancer.